Champions Oncology, Inc.

Did you miss our webinar? Watch it ON-DEMAND! This dynamic webinar provided a thorough analysis of Champions' revolutionary TumorGraft3D platform, a proprietary ex vivo multiclonal 3D organ-like tumor culture assay derived from our industry-leading clinically relevant patient-derived xenograft (PDX) models, including industry-relevant case studies. Watch on-demand: https://hubs.li/Q02v5GPF0 #organoid #3Dcultures #exvivo #PDXmodels #3D #oncologyresearch #preclinical #flowcytometry #HCI #DRUGseq

Have you encountered difficulties finding a specialty testing provider that prioritizes clinical regulatory compliance, providing results that you can trust? Our latest blog discusses clinical regulatory standards and accreditations as crucial pillars for robust clinical trial data. Learn about the fundamentals of GCLP, CLIA, and CAP standards and why they are vital for successful research. Read our blog to learn more: https://hubs.li/Q02v1HyV0 As your trusted clinical specialty testing provider, we ensure: ✅ Data results are of the highest quality, ensuring reliability and reproducibility while maintaining strict adherence to QA standard operating procedures (SOPs). ✅ Our results maintain cross-compatibility across global sites and state-of-the-art instrumentation. ✅ Prospective and current clients are welcome to visit our cutting-edge laboratories and meet our team of experts for thorough due diligence and in-study audits. Learn more about regulatory compliance frameworks and Champions’ clinical specialty testing capabilities for your upcoming clinical trial. #regulatorycompliance #GCLP #CLIA #CAP #clinicalspecialitytesting #oncology #cancerresearch 

Accelerate your oncology research with superior model selection and AI-powered analytics. Lumin is an integrated software solution that grants you an unparalleled view into intricate genomic, proteomic, and pharmacological profiles from Champions’ proprietary patient-derived preclinical models, empowering researchers to identify the most promising models for their studies with precision and ease. Start your free trial now: https://hubs.li/Q02tXz3y0

✨ Register Now! ✨ Join us for TOMORROW'S webinar providing a thorough analysis of Champions' revolutionary TumorGraft3D platform, a proprietary ex vivo multiclonal 3D organ-like tumor culture assay derived from our industry-leading clinically relevant patient-derived xenograft (PDX) models. Attend this webinar to: ✔ Gain comprehensive insights into the TumorGraft3D platform and its robust capabilities ✔ Discover specific readouts including cytotoxicity, flow cytometry, high-content imaging, DRUGseq, and luciferase-tagged models for superior research outcomes ✔ Understand the applications of the platform to refine your preclinical programs Register to attend live or on-demand: https://hubs.li/Q02tNHNT0 #organoid #3Dcultures #exvivo #PDXmodels #3D #oncologyresearch #preclinical #flowcytometry #HCI #DRUGseq

Are you attending the 18th WRIB (Workshops on Recent Issues in Bioanalysis) in San Antonio? Our team of experts will be on-site at booth #61 to discuss how Champions can support your upcoming global clinical trials with specialty testing. Schedule a meeting today: https://hubs.li/Q02tzfnK0 #WRIB2024 #biomarkers #immunooncology #immunotherapy #Cancerresearch #oncology #clinicaltrials #clinicalspecialtytesting #flowcytometry

Are you looking for a robust Western blot assay with high sensitivity to support your preclinical studies? Champions' advanced Western Blot platform was developed by our experts for target validation, model and sample characterization, detection of post-translational modifications, and more... Our assay platform delivers: ✅ Sensitivity at the picogram level, requiring only a few microliters of sample. ✅ Enhanced data quality and reproducibility through automated protein separation and immunodetection. ✅ Tailored assays with rapid turnaround to meet your unique needs. ✅ Compatibility with all of Champion's preclinical pharmacology platforms and clinical specialty testing. Count on Champions for precise and dependable Western Blot Assay for your preclinical studies. Reach out today to discuss how we can accelerate your research: https://hubz.li/Q02tdjGR0 #westernblot #Proteindetection #Drugdiscovery #Cancerresearch #oncology #medicinalchemistry

Did you know that pre-treated PDX tumor models offer exclusive insights into drug resistance mechanisms in cancer therapy? Dive into Champions' latest blog to explore how our expansive, highly characterized biobank of pre-treated PDX models helps researchers devise superior strategies to overcome drug resistance. With a repository of over 1,000 pre-treated tumor models sourced from 60+ tumor types, Champions' PDX biobank offers researchers an unparalleled resource. Our pre-treated models offer a unique platform to probe resistance mechanisms in models closely mimicking the molecular and cellular characteristics of the original patient tumors. Key features of Champions' PDX biobank include: ✅Models derived from advanced-stage primary and metastatic tumors, representing diverse tumor stages. ✅Pre-treated models with a range of therapies, enabling comprehensive exploration of resistance mechanisms. ✅Accessible through Lumin for precise model selection based on clinical characteristics, facilitating tailored studies. ✅Ideal for evaluating therapeutics in a setting that mirrors the real-world patient population, thus mitigating drug development risks. Explore our blog to uncover how these models can accelerate the development of your advanced cancer treatments, bringing better cancer treatments to patients worldwide. #CancerResearch #DrugDiscovery #PDXModels #Oncology #TumorModels https://hubs.li/Q02tn0Wc0

Do you have cryopreserved PBMC clinical samples waiting for processing and analysis? As your Clinical Specialty Testing partner, Champions Oncology has many off-the-shelf GCLP-compliant high-complexity flow cytometry panels that have been optimized and validated in cryopreserved PBMCs, allowing for immediate processing and analysis, and minimizing your timelines. Learn more about our clinical flow cytometry panels: https://hubs.li/Q02t9p1n0 #clinicalflowcytometry #flowcytometry #CryopreservedPBMCs #GCLP

ENROLL TODAY in Champions' Systemic AML In Vivo Screen to evaluate the efficacy of your therapeutics, featuring 30 never-passaged primary AML models. This screen provides reliable full-characterization results including multi-omics datasets, encompassing NGS (WES and RNAseq), proteomics, phospho-proteomics, and kinase activity. These models closely mimic real disease conditions, representing various stages of malignancies, allowing for selection of the best AML models to assess your therapeutics. Our latest Systemic AML In Vivo Screen features: ✅ 2 AML models from patients refractory to gilteritinib, 5-azacitidine, and venetoclax ✅ Flow cytometry analysis on peripheral blood and bone marrow ✅ Plasma-based Luminex Enroll in Champions' Systemic AML In Vivo Screen before April 30th, 2024 ➡️https://hubs.li/Q02sTFlc0 #Oncology #CancerResearch #AML #hematologicalmalignancy #leukemia #drugscreening #drugdiscovery

Join us for an upcoming webinar that provides thorough analysis of Champions' revolutionary TumorGraft3D platform, a proprietary ex vivo multiclonal 3D organ-like tumor culture assay derived from our industry-leading clinically relevant patient-derived xenograft (PDX) models. Attend this webinar to: ✔ Gain comprehensive insights into the TumorGraft3D platform and its robust capabilities ✔ Discover specific readouts including cytotoxicity, flow cytometry, high-content imaging, DRUGseq, and luciferase-tagged models for superior research outcomes ✔ Understand the applications of the platform to refine your preclinical programs Register to attend live or on-demand: https://hubs.li/Q02sC1-J0 #organoid #3Dcultures #exvivo #PDXmodels #3D #oncologyresearch #preclinical #flowcytometry #HCI #DRUGseq